Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.

Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC Jr.

Clin Cancer Res. 2000 Aug;6(8):3334-41.

2.

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr.

Int J Cancer. 1999 Aug 12;82(4):525-31.

3.
4.

Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.

Bast RC Jr, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A.

Hybridoma. 1998 Aug;17(4):313-21.

PMID:
9790065
5.

A linear region of a monoclonal antibody conformational epitope mapped on p185HER2 oncoprotein.

Orlandi R, Formantici C, Ménard S, Boyer CM, Wiener JR, Colnaghi M.

Biol Chem. 1997 Nov;378(11):1387-92.

PMID:
9426199
7.

Radioiodinated antibody targeting of the HER-2/neu oncoprotein.

Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC Jr, Zalutsky MR.

Nucl Med Biol. 1997 Jul;24(5):451-9.

PMID:
9290082
8.

Expression of cell regulatory proteins in ovarian borderline tumors.

van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC Jr, Hacker NF.

Cancer. 1996 May 15;77(10):2092-8.

PMID:
8640675
9.

Molecular approaches to prevention and detection of epithelial ovarian cancer.

Bast RC Jr, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A.

J Cell Biochem Suppl. 1995;23:219-22. Review.

PMID:
8747399
10.

Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides.

Orlandi R, Ménard S, Colnaghi MI, Boyer CM, Felici F.

Eur J Immunol. 1994 Nov;24(11):2868-73.

PMID:
7525309
11.
12.

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, et al.

Nature. 1994 Aug 18;370(6490):558-61.

PMID:
8052311
13.
14.

Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.

Bast RC Jr, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM.

Immunol Ser. 1994;61:23-30. Review. No abstract available.

PMID:
7912111
15.

Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.

McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr.

Cancer. 1993 Jun 15;71(12):3942-6.

PMID:
8099528
16.
17.

Cell growth regulation in epithelial ovarian cancer.

Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A.

Cancer. 1993 Feb 15;71(4 Suppl):1597-601. Review.

PMID:
8431895
18.

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr.

Int J Cancer. 1993 Feb 1;53(3):401-8.

PMID:
7679090
19.

Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr.

Cancer. 1992 Oct 15;70(8):2137-42.

PMID:
1394043
20.

A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines.

Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, DeSombre K, George SL, Boyer CM, Argon Y, et al.

Int J Cancer. 1992 Jul 9;51(5):772-9.

PMID:
1351885
21.

Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.

Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr.

Am J Obstet Gynecol. 1992 Mar;166(3):997-1007.

PMID:
1550178
22.

Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC Jr.

Cancer Res. 1991 Oct 1;51(19):5361-9.

23.

Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.

Tyson FL, Boyer CM, Kaufman R, O'Briant K, Cram G, Crews JR, Soper JT, Daly L, Fowler WC Jr, Haskill JS, et al.

Am J Obstet Gynecol. 1991 Sep;165(3):640-6.

PMID:
1679963
24.

Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ.

Cancer Res. 1991 Jun 1;51(11):2908-16.

25.

Induction of HLA-specific CTL to nonimmunogenic, heat-inactivated lymphocytes by interleukin 2.

Brissette-Storkus CS, Kostyu DD, Boyer CM, Dawson JR.

Transplantation. 1990 Nov;50(5):862-9.

PMID:
2238061
26.

Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.

Yu YH, Crews JR, Cooper K, Ramakrishnan S, Houston LL, Leslie DS, George SL, Lidor Y, Boyer CM, Ring DB, et al.

Cancer Res. 1990 Jun 1;50(11):3231-8.

27.

Heterogeneity of antigen expression in advanced epithelial ovarian cancer.

Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC Jr.

Am J Obstet Gynecol. 1990 Apr;162(4):883-8.

PMID:
2327461
28.

The role of peptide growth factors in epithelial ovarian cancer.

Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC Jr, Boyer CM.

Obstet Gynecol. 1990 Feb;75(2):255-62.

PMID:
2300354
29.
30.

Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.

Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB, McCarty KS Jr, Bast RC Jr.

Cancer Res. 1989 Apr 15;49(8):2091-5.

31.

Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells.

Boyer CM, Borowitz MJ, McCarty KS Jr, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC Jr.

Int J Cancer. 1989 Jan 15;43(1):55-60.

PMID:
2463226
32.

A study of the functions of continuing nursing education administrators.

Boyer CM.

J Contin Educ Nurs. 1989 Jan-Feb;20(1):40-2. No abstract available.

PMID:
2492319
33.

Notes in continuing education. Bread and butter courses.

Crandall SG, Boyer CM.

J Contin Educ Nurs. 1987 Sep-Oct;18(5):180. No abstract available.

PMID:
3116057
34.

Notes on CE. Business success.

Boyer CM.

J Contin Educ Nurs. 1987 Jul-Aug;18(4):140. No abstract available.

PMID:
3112197
35.

The North Dakota decision on entry into practice; how it happened--what it means in Pennsylvania.

Boyer CM.

Pa Nurse. 1987 Apr;42(4):14. No abstract available.

PMID:
3646587
36.

Functional defect of heat-inactivated human lymphocytes in mixed-lymphocyte culture.

Boyer CM, Kostyu DD, Brissette CS, Amos DB.

Cell Immunol. 1986 Sep;101(2):440-53.

PMID:
2944610
37.

The international connection: a view of continuing professional education in the U.S.S.R.

Boyer CM.

J Contin Educ Nurs. 1986 Mar-Apr;17(2):50-3. No abstract available.

PMID:
3081608
38.

Quantitation of the Sm nuclear antigen in tissues and activated lymphocytes.

Boyer CM, Eisenberg RA, Cohen PL.

Arthritis Rheum. 1985 Mar;28(3):294-9.

PMID:
3977975
39.

Accreditation and continuing education in nursing: a state nurses' association perspective.

Boyer CM.

J Contin Educ Nurs. 1983 Mar-Apr;14(2):19-23. No abstract available.

PMID:
6404961
40.
41.

Performance-based staff development: the cost-effective alternative.

Boyer CM.

Nurse Educ. 1981 Sep-Oct;6(5):12-5. No abstract available.

PMID:
6792571
42.

Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.

Boyer CM, Kreider JW, Bartlett GL.

Cancer Res. 1981 Jun;41(6):2394-400.

43.

Effective use of supplemental nurses.

Boyer CM.

Health Serv Manager. 1979 Nov;12(11):4-6. No abstract available.

PMID:
10244168
44.
45.

The use of supplemental nurses: why, where, how?

Boyer CM.

J Nurs Adm. 1979 Mar;9(3):56-60.

PMID:
253745
46.

The answer doesn't always come prepackaged.

Boyer CM.

Nurse Educ. 1978 Mar-Apr;3(2):17-8. No abstract available.

PMID:
245572
47.

Caring for a young addict with tetanus.

Boyer CM.

Am J Nurs. 1974 Feb;74(2):265-7. No abstract available.

PMID:
4492221

Supplemental Content

Loading ...
Support Center